Moxabustão associada à vincristina no tratamento do tumor venéreo transmissível

Abstract

Transmissible Venereal Tumor (TVT) is a type of round cell neoplasm specific to canine, which occurs by implantation of tumor cells in the mucosa during coitus and thus the external genitals become most affecteds site. The moxatherapy is an ancient therapeutic technique of Traditional Chinese Medicine, which has the same foundations as acupuncture with the insertion of needles, however, moxatherapy comprises heating acupoints, zones and meridians on the skin, through the combustion of medicinal herbs. The purpose of this study was to demonstrate the effect of moxibustion associated with vincristine sulfate in the treatment of TVT. For this purpose, 12 dogs were selected (Canis lupus familiaries), with positive diagnosis for TVT, without taking into account race, sex, age, sexual situation and whether they were semi-domiciled or not. These were previously submitted to a general clinical examination, in addition to laboratory tests, such as blood count and cytological examination of the tumor mass. The dogs were randomly divided into control group (CG) and moxatherapy group (GM). Most of the animals in this study were considered a risk group for TVT, mixed breed dogs (100%), females (91.66%), with average age between three and five years and free access to the streets (41.66%). Chemotherapy using vincristine sulfate at a dose of 0.025mg/Kg On the other hand, the use of the moxibustion technique did not result in a significant effect on the number of chemotherapy sessions needed (p-value = 0.34). When considering the number of sessions for tumor remission and the hematological profile of the animals, it was noted that the GM and CG groups were similar and that there was no difference (p>0.05) in all analyzed variables. And that regardless of the type of treatment used, the number of sessions needed varied from 4 to 8. Therefore, it can be concluded that there was no effect of moxibustion, when associated with vincristine sulfate, in the treatment of transmissible venereal tumors.